Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 21.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,953,472 shares, an increase of 21.1% from the February 26th total of 1,613,558 shares. Currently, 5.1% of the company’s shares are short sold. Based on an average daily volume of 918,838 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analyst Weigh In

SABS has been the subject of a number of research analyst reports. Chardan Capital lifted their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. HC Wainwright dropped their target price on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. UBS Group initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 price target for the company. Finally, Guggenheim assumed coverage on SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Trading of SAB Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SABS. State of Wyoming purchased a new position in SAB Biotherapeutics during the 4th quarter worth $34,000. State Street Corp purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at about $49,000. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics in the third quarter worth about $30,000. Fifth Lane Capital LP acquired a new stake in SAB Biotherapeutics in the fourth quarter worth about $56,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $32,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Up 1.3%

NASDAQ:SABS opened at $3.83 on Wednesday. The company’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $3.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The stock has a market capitalization of $195.14 million, a P/E ratio of -1.65 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). On average, equities analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.